IS OUR MISSION
Reasons why we do what we do and lead us to our mission: Improve early breast cancer diagnosis
HIGH INCIDENCE OF BREAST CANCER
TECHNOLOGICAL LIMITATIONS
Metabolic information
Portable, no infrastructure required
High specificity
No specialized operator and autonomous
No ionizing radiation.
Suitable for all patients
Pamela Pardini, PhD / CEO Nicolás Carbone, PhD / CTO
Alberto Rodriguez Navarro, MD Sergio Richter, BioEng Nicolás Carbone, PhD / CTO
Pamela Munter, MD
Daniela Iriarte, Physicist, PdD
Demian Vera, Physicist, MSc
Héctor García, Physicist, PhD
Héctor Oscar Di Rocci, Physicist, PhD
Juan Pomarico, Physicist, PhD
L Mariel Bernal, BioEng, BA
M. Victoria Waks Serra, Physicist, PhD
Foundation of Biomedical Optics Group
Optical mammography device idea
Prendete award
IB50k Award
Birth of Bionirs
CITES investment
BIONIRSFollow
ENLIGHTENING BIOMEDICINE - We are a startup from Argentina, looking for diagnosis Solutions by means of light #Startups #breastcancer contacto@bionirs.com
@BIONIRS_ok https://twitter.com/Nicolas_Domke/status/1374075282651500545
The New Insider Game In Latin America Biotech. @CHBionegocios & #Zentynel partners are launching a USD$60 million Fund focused on the best biotech assets available in Latin America to address pressing global challenges cc @Hub_APTA @gridexp @mpeire https://invivo.pharmaintelligence.informa.com/IV124728/The-New-Insider-Game-In-Latin-America-Biotech
UNICEN Campus Universitario – Tandil, Buenos Aires, Argentina contacto@bionirs.com
No ionizing radiation.
Alberto Rodriguez Navarro, MD
UNICEN Campus Universitario – Tandil, Buenos Aires, Argentina contacto@bionirs.com
UNICEN Campus Universitario – Tandil, Buenos Aires, Argentina contacto@bionirs.com
Follow us!
bionirs
BIONIRSFollow
ENLIGHTENING BIOMEDICINE - We are a startup from Argentina, looking for diagnosis Solutions by means of light #Startups #breastcancer contacto@bionirs.com
@BIONIRS_ok https://twitter.com/Nicolas_Domke/status/1374075282651500545
The New Insider Game In Latin America Biotech.
@CHBionegocios & #Zentynel partners are launching a USD$60 million Fund focused on the best biotech assets available in Latin America to address pressing global challenges cc @Hub_APTA @gridexp @mpeire
https://invivo.pharmaintelligence.informa.com/IV124728/The-New-Insider-Game-In-Latin-America-Biotech